Alnylam Pharma (ALNY) Appoints Elliott Sigal to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
August 24, 2022 4:00 PM EDTDr. Sigal Brings Decades of Leadership Experience at Biopharmaceutical Companies
Served as Chief Scientific Officer and a Director of Bristol-Myers Squibb
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced... More
